

## Board change - Executive appointment

Melbourne, Australia, 23 May 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces that Company Director, John Livingston, has been appointed into an Executive position with the Company in the role of Senior Strategist and Executive Director.

Mr Livingston has significant commercial experience in relation to business strategies, sales and systems in the digital radiology environment. Having previously been the CEO and Managing Director of Integral Diagnostics (ASX:IDX), Mr Livingston is well placed to add value to 4DMedical’s sales initiatives.

Mr Livingston will be responsible for helping to drive sales revenue and will also assist by representing 4DMedical at conferences and in communications with key partners. The Executive Director role has the same general legal responsibilities as any other director of 4DMedical Limited.

The Board advises that John Livingston has entered into an employment agreement with the Company and in accordance with ASX Listing Rule 3.16.4, the new terms of Mr Livingston’s remuneration package are as follows:

<b>Title</b>	Senior Strategist and Executive Director
<b>Effective Date</b>	1 May 2022
<b>Base Remuneration</b>	\$100,000 (excluding superannuation) per annum
<b>Incentives</b>	Up to 636,576 options available, over a 3-year period, with vesting conditions tied to Australian and New Zealand revenue milestones.
<b>Notice period for termination</b>	3 months

-ENDS-

Authorised by the 4DMedical Board of Directors.

### Contacts

#### **Corporate**

Melanie Leydin  
Company Secretary  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### **Media**

Julia Maguire  
+ 61 419 815 386  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

### About 4DMedical

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company focused on delivering the global gold standard in respiratory diagnostics for all lung disorders, including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.



The unique and transformative XV Technology™ accurately and quickly scans lung function as the patient breathes, enabling early diagnosis and the monitoring of changes over time.

Our Software-as-a-Service (SaaS) delivered Ventilation Reports provide information and insights far beyond the capabilities of conventional modalities, showing subtle variations in lung function down to the finest details in specific regions of each lung, and with lower exposure to radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. 4DMedical is disrupting this sector and is committed to providing better information to doctors and patients about lung function.

*Better information means better decisions and better outcomes.*

Learn more: <https://4dmedical.com>